Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,663 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02531308 | Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)(DLBCL) | terminated | Phase 2 | 5 | Rush University Medical CenterOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT02572453 | Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 13, 2022 | clinicaltrials |
| NCT03379051 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL | terminated | Phase 1 / Phase 2 | 78 | TG Therapeutics, Inc.INDUSTRY | 1 | Aug 22, 2022 | clinicaltrials |
| NCT03422523 | Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy(ARGO) | terminated | Phase 2 | 53 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT02361346 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL(MT-3724NHL001) | terminated | Phase 1 / Phase 2 | 38 | Molecular Templates, Inc.INDUSTRY | 10 | Aug 18, 2022 | clinicaltrials |
| NCT03488251 | PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 8 | Molecular Templates, Inc.INDUSTRY | 1 | Aug 16, 2022 | clinicaltrials |
| NCT01464034 | A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 136 | Criterium, Inc.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT02793583 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma(UNITY-NHL) | terminated | Phase 2 / Phase 3 | 710 | TG Therapeutics, Inc.INDUSTRY | 9 | Jul 21, 2022 | clinicaltrials |
| NCT03207256 | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials | terminated | Phase 2 | 51 | TG Therapeutics, Inc.INDUSTRY | 1 | Jul 21, 2022 | clinicaltrials |
| NCT00464178 | A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 7 | Hackensack Meridian HealthOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT01241786 | Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL(VZCLLPI0146) | terminated | Phase 2 | 5 | Hackensack Meridian HealthOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT01555281 | Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma | terminated | Phase 1 / Phase 2 | 33 | Swiss Cancer InstituteOTHER | 2 | Jul 7, 2022 | clinicaltrials |
| NCT02374424 | Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients(GIOTTO) | terminated | Phase 2 | 29 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT03256045 | Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 9 | University of WashingtonOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT03303950 | Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis | terminated | Phase 2 | 6 | University of UtahOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT03850522 | PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma | terminated | Phase 2 | 6 | Lene Meldgaard KnudsenOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT04155840 | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 1 | University of WashingtonOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT03312868 | Stereotactic Body Radiotherapy for the Treatment of Solitary Bone Plasmacytoma | terminated | Phase 2 | 10 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02420795 | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03104270 | Combination Study for High Risk Multiple Myeloma Patients | terminated | Phase 2 | 13 | OncotherapeuticsINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02356458 | Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma | terminated | Phase 1 / Phase 2 | 58 | Swiss Cancer InstituteOTHER | 3 | Mar 11, 2022 | clinicaltrials |
| NCT04209621 | Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | terminated | Phase 2 | 3 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 9, 2022 | clinicaltrials |
| NCT01685606 | Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma(273) | terminated | Phase 2 | 6 | Brown UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT00792506 | Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 1 | ItalfarmacoINDUSTRY | 1 | Feb 2, 2022 | clinicaltrials |
| NCT03875495 | A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) | terminated | Phase 1 / Phase 2 | 9 | Genenta ScienceINDUSTRY | 1 | Jan 28, 2022 | clinicaltrials |
| NCT00792831 | Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia | terminated | Phase 2 | 3 | ItalfarmacoINDUSTRY | 1 | Jan 27, 2022 | clinicaltrials |
| NCT04097301 | Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | terminated | Phase 1 / Phase 2 | 8 | AGC Biologics S.p.A.INDUSTRY | 2 | Jan 19, 2022 | clinicaltrials |
| NCT03153514 | Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation(CLLTX1) | terminated | Phase 2 | 3 | German CLL Study GroupOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT03954106 | A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity | terminated | Phase 2 | 25 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 9, 2021 | clinicaltrials |
| NCT00479167 | A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma | terminated | Phase 2 | 1 | Rush University Medical CenterOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT01585688 | Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL | terminated | Phase 1 / Phase 2 | 13 | Gilead SciencesINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT01045382 | MSC and HSC Coinfusion in Mismatched Minitransplants | terminated | Phase 2 | 39 | University of LiegeOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT00113802 | Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia | terminated | Phase 2 | 31 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT01101594 | A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 17 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT02489123 | Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 8 | University of WashingtonOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT03634800 | Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)(RISE-M) | terminated | Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT01946152 | Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT01434472 | High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma | terminated | Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT03178201 | TGR1202 in Relapsed and Refractory Follicular Lymphoma | terminated | Phase 2 | 5 | Columbia UniversityOTHER | 1 | Jul 16, 2021 | clinicaltrials |
| NCT00445068 | Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma | terminated | Phase 2 | 38 | Novartis PharmaceuticalsINDUSTRY | 2 | Jul 14, 2021 | clinicaltrials |
| NCT03567616 | A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 8 | AbbVieINDUSTRY | 3 | Jun 30, 2021 | clinicaltrials |
| NCT02128230 | UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | terminated | Phase 2 | 20 | University of ArkansasOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT02323230 | A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL | terminated | Phase 2 | 4 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 1 | Jun 22, 2021 | clinicaltrials |
| NCT02757326 | ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma(ABC-103) | terminated | Phase 1 / Phase 2 | 13 | RedHill Biopharma LimitedINDUSTRY | 1 | Jun 18, 2021 | clinicaltrials |
| NCT03687125 | Tinostamustine Conditioning and Autologous Stem Cell(TITANIUM1) | terminated | Phase 1 / Phase 2 | 6 | Mundipharma-EDO GmbHINDUSTRY | 3 | Jun 18, 2021 | clinicaltrials |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | terminated | Phase 2 / Phase 3 | 40 | Kiadis PharmaINDUSTRY | 7 | Jun 14, 2021 | clinicaltrials |
| NCT03520985 | Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma(OptiPOM) | terminated | Phase 2 | 34 | Swiss Cancer InstituteOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT00003511 | Antineoplaston Therapy in Treating Patients With Multiple Myeloma | terminated | Phase 2 | 5 | Burzynski Research InstituteOTHER | 1 | Jun 9, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Sep 28, 2022source: clinicaltrials